Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 47Terminated 4Withdrawn 3Recruiting 3Active not recruiting 2Unknown 1Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Lymphoid 2Gynecologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × MLN 8237 × Clear all
NCT02367352 2019-06-26

Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors

Takeda

Phase 1 Terminated
9 enrolled 14 charts
GynecologicThoracic

Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT01812005 2018-06-06

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
14 enrolled 11 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01471964 2018-05-17

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Fox Chase Cancer Center

Phase 1/2 Terminated
22 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

NCT02700022 2017-11-20

A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas

UNC Lineberger Comprehensive Cancer Center

Phase 1 Terminated
1 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡